Product Pathways - Neuroscience
Alzheimer Disease Antibody Sampler Kit #9784
|Kit Includes||Quantity||Applications||Reactivity||MW (kDa)||Isotype|
|β-Amyloid (D54D2) XP® Rabbit mAb #8243||40 µl||W IP IF-P||H M||5||Rabbit IgG|
|Neurofilament-L (C28E10) Rabbit mAb #2837||40 µl||W IHC-P IF-F||H M R||70||Rabbit IgG|
|Tau (Tau46) Mouse mAb #4019||40 µl||W IHC-P IF-P IF-F||H M R (B)||50 to 80||Mouse IgG1|
|BACE (D10E5) Rabbit mAb #5606||40 µl||W IP||H M R||70||Rabbit IgG|
|APP/β-Amyloid (NAB228) Mouse mAb #2450||40 µl||W IHC-P IF-P||H Mk B (Dg) (Pg)||100 to 140||Mouse IgG2a|
|α-Synuclein (Syn204) Mouse mAb #2647||40 µl||W IHC-P||H||18||Mouse IgG2a|
|GSK-3α/β (D75D3) XP® Rabbit mAb #5676||40 µl||W IP IF-IC||H M R Hm Mk||51, 46||Rabbit IgG|
|Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb #9316||40 µl||W IHC-P||H M R Mk||51||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||Goat|
|Anti-mouse IgG, HRP-linked Antibody #7076||100 µl||Horse|
Reactivity Key: H=Human M=Mouse R=Rat Hm=Hamster Mk=Monkey B=Bovine Dg=Dog Pg=Pig
Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Specificity / Sensitivity
β-Amyloid (D54D2) XP® Rabbit mAb recognizes endogenous levels of total β-amyloid peptide (Aβ). The antibody detects several isoforms of Aβ, such as Aβ-37, Aβ-38, Aβ-39, Aβ-40, and Aβ-42. APP/β-Amyloid (NAB228) Mouse mAb detects endogenous levels of APP/β-Amyloid protein. Although this antibody recognizes both the phospho and non-phospho forms of the protein, it has been shown to prefer the phosphorylated form in some systems. BACE (D10E5) Rabbit mAb detects endogenous levels of total BACE protein. Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb detects endogenous levels of GSK-3α protein when phosphorylated at Ser21, and does not detect GSK-3β when phosphorylated at Ser9. GSK-3α/β (D75D3) XP® Rabbit mAb detects endogenous levels of total GSK-3α and GSK-3β protein. The antigen is 100% conserved between GSK-3α and GSK-3β in humans, monkeys, mice, and rats. Neurofilament-L (C28E10) Rabbit mAb detects endogenous levels of total Neurofilament-L protein. α-Synuclein (Syn204) Mouse mAb detects endogenous levels of total synuclein protein. This antibody detects recombinant α but not β-synuclein (Giasson, B.I. et al., 2000). Tau (Tau46) Mouse mAb detects endogenous levels of total tau protein, and also cross-reacts with MAP2 at 280 kDa. This antibody is predicted to detect all six isoforms of tau based on the amino acid sequence.
Western blot analysis of extracts from HeLa and SK-N-MC cells using APP/β-Amyloid (NAB228) Mouse mAb #2450.
Western blot analysis of extracts from human cerebellum and HeLa cells using α-Synuclein (Syn204) Mouse mAb #2647.
Western blot analysis of extracts from mouse brain, HeLa cells, and rat brain using Neurofilament-L (C28E10) Rabbit mAb #2837.
Western blot analysis of extracts from mouse and rat brain using Tau (Tau46) Mouse mAb #4019.
Western blot analysis of extracts from HeLa cells, untransfected and BACE transfected, and rat brain extracts using BACE (D10E5) Rabbit mAb #5606.
Western blot analysis of extracts from HeLa and COS-7 cells using GSK-3α/β (D75D3) XP® Rabbit mAb #5676.
Western blot analysis of human Aβ-42, Aβ-40, Aβ-39, Aβ-38, and Aβ-37 peptides (5 ng) using β-Amyloid (D54D2) XP® Rabbit mAb #8243.
The Alzheimer Disease Antibody Sampler Kit provides an economical means of evaluating Alzheimer Disease-related signaling. The kit contains enough primary and secondary antibodies to perform four western blot experiments per primary antibody.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human ß-amyloid peptide (Aß), surrounding Glu450 of human Neurofilament-L protein, native bovine tau protein (carboxy terminus), a synthetic peptide corresponding to residues surrounding Asp490 of human BACE protein, human recombinant α-synuclein protein (amino terminus), ß-amyloid protein (amino terminus) (Lee et al., 2003), a synthetic peptide surrounding Gln269 of human GSK-3α protein, or a synthetic phosphopeptide corresponding to residues surrounding Ser21 of human GSK-3α protein
Alzheimer Disease (AD) is one of the most common neurodegenerative diseases worldwide. Clinically, it is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles, which results in neuronal dysfunction and cell death. Central to this disease is the differential processing of the integral transmembrane glycoprotein Amyloid β (A4) precursor protein (APP) that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). β-secretase (BACE) is an aspartic acid proteinase that catalyses the initial step in APP processing by cleaving and releasing a soluble, extracellular APP-β (sAPPβ) ectodomain and generating a membrane-bound, carboxy-terminal fragment consisting of 99 amino acids (CTF99). Additional processing of CTF99 by γ-secretase generates the amyloid β-peptide (Aβ) that forms aggregates in the brains of AD patients. BACE is an attractive target for inhibitors in AD therapy since it catalyses the first and rate limiting step in amyloidogenic APP processing (2). Pro-BACE-1 is synthesized in the ER before it is transported to the trans-Golgi network to undergo maturation (3). The extracellular deposition and accumulation of the released Aβ fragments and an α-synuclein fragment known as the non- Aβ fragment, form the main components of amyloid plaques in AD. GSK-3α regulates the production of Aβ peptides. Administration of therapeutic concentrations of lithium, a GSK-3 inhibitor, attenuates Aβ production by specifically inhibiting the cleavage of APP by γ-secretase, thereby blocking accumulation of Aβ peptides in the brains of mice that overproduce APP (4). AD is also characterized by the presence of neurofibrillary tangles. These tangles are the result of hyperphosphorylation and oligomerization of the microtubule associated protein Tau and lead to apoptosis of the neuron. In particular, phosphorylation of Tau Ser396 by GSK-3 or CDK5 destabilizes microtubules in AD (5,6). Additionally, neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM) and heavy (NFH) subunits (7). Accumulation of neurofilaments are found in many human neurological disorders including AD (7).
- Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
- Hunt, C.E. and Turner, A.J. (2009) FEBS J 276, 1845-59.
- Walter, J. et al. (2001) J Biol Chem 276, 14634-41.
- Phiel, C.J. et al. (2003) Nature 423, 435-9.
- Johnson, G.V. and Stoothoff, W.H. (2004) J Cell Sci 117, 5721-9.
- Bramblett, G.T. et al. (1993) Neuron 10, 1089-99.
- Al-Chalabi, A. and Miller, C.C. (2003) Bioessays 25, 346-55.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7003 20X LumiGLO® Reagent and 20X Peroxide
- 9998 BSA
- 9999 Nonfat Dry Milk
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7722 Blue Loading Buffer Pack
- 4147 Cleaved Notch1 (Val1744) (D3B8) Rabbit mAb
- 2452 APP Antibody
- 8112 SignalStain® Antibody Diluent
- 2835 Neurofilament-L (DA2) Mouse mAb
- 2836 Neurofilament-H (RMdO 20) Mouse mAb
- 2838 Neurofilament-M (RMO 14.9) Mouse mAb
- 9338 GSK-3α Antibody
- 9337 Phospho-GSK-3α (Ser21) (46H12) Mouse mAb
- 9910 Phospho-MAPK Family Antibody Sampler Kit
- 4542 MAP2 Antibody
- 3976 TACE Antibody
- 3823 Phospho-APP (Thr668) Antibody
- 2642 α-Synuclein Antibody
- 2644 α/β-Synuclein (Syn205) Mouse mAb
- 3622 Presenilin 1 Antibody
- 9322 Phospho-GSK-3-beta (Ser9) (D3A4) Rabbit mAb
- 4818 GSK-3α (D80D1) XP® Rabbit mAb
- 9315 GSK-3β (27C10) Rabbit mAb
- 9632 Phospho-Tau (Ser396) (PHF13) Mouse mAb
For Research Use Only. Not For Use In Diagnostic Procedures.